From ambition to delivery: is the National Cancer Plan properly funded?

In February 2026, the UK Government unveiled its National Cancer Plan, the first dedicated cancer strategy for England in over a decade. As the Plan moves from ambition to delivery, questions arise about whether it is properly funded. Emma Spencelayh and Momoko Bowles examine the Plan's funding and delivery, and how it measures up to its commitments.

The Government's ambition is to boost cancer survival to world-leading levels, and proper funding is crucial, especially as the ageing population means more people will get cancer in the coming years. Investment in cancer services also makes economic sense, as cancer deaths cost the UK £10 billion annually in lost productivity, with the potential to add 8,000 full-time workers to the economy if survival rates match those of similar countries.

The Plan includes funding for specific initiatives, such as £80 million for specialist pharmacies and £70 million for smoking cessation services. However, not all commitments are backed by clear funding, particularly those related to innovation. While increased productivity is expected to help free up capacity, cancer case numbers have been increasing annually, and it remains unclear if productivity gains alone will be enough to support the Plan.

The Plan has acknowledged workforce pressures, but there is limited focus on the wider workforce. The Department of Health and Social Care's 10 Year Capital Plan references some funding but does not mention key commitments made in the Cancer Plan, raising concerns about the overall approach to funding cancer transformation.